2026 NPPES data Oncology Pharmacist NPI 1952791071 PHARM.D., BCOP
Verify on CMS →

STEPHANIE MAGDANZ, PHARM.D., BCOP

Oncology Pharmacist in BOISE, Idaho. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
72
Medicare Part D claims · 64 beneficiaries · Oncology Pharmacist avg: 160
Generic prescribing
4%
generic claims · 96% brand-name · higher generic rates reduce patient out-of-pocket costs
What the federal data reveals: STEPHANIE MAGDANZ, PHARM.D., BCOP is a Oncology Pharmacist ([object Object]) practicing in BOISE, Idaho with a Medicare Part D prescribing footprint of 72 claims across 64 beneficiaries — 96% brand-name prescribing .

What stands out: STEPHANIE MAGDANZ, PHARM.D., BCOP filed 72 Medicare Part D claims in 2023 across BOISE, Idaho. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

STEPHANIE MAGDANZ, PHARM.D., BCOP at a glance

Quality data not reported

NPI registry status

Active

Issued 01/27/2015

NPI 1952791071

Primary specialty

Oncology Pharmacist

Niche

1,699 US NPIs in this specialty

Medicare Part D claims

72 55% vs specialty avg

2023 prescription claims

Specialty avg: 160

Specialty distribution in Idaho

How Oncology Pharmacist compares to other specialties among Idaho providers

Idaho providers

Oncology Pharmacist share within Idaho

1. Oncology Pharmacist42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Oncology Pharmacist share within Idaho

Specialty board-certification context

Estimated specialty board-certified rate — Oncology Pharmacist (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Oncology Pharmacist ABMS/AOA estimate

Est. board-certified rate (Oncology Pharmacist) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Oncology Pharmacist) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

STEPHANIE MAGDANZ, PHARM.D., BCOP is a Oncology Pharmacist provider practicing in BOISE, Idaho, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: PHARM.D., BCOP. NPI: 1952791071. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

STEPHANIE MAGDANZ, PHARM.D., BCOP appears in the CMS NPPES registry as a Oncology Pharmacist provider holding PHARM.D., BCOP credentials at 500 W FORT ST, BOISE, ID, 83702, with a listed phone of (208) 422-1000. NPI 1952791071 was issued on 01/27/2015. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what MAGDANZ most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 72 prescription claims written by this provider, covering 64 Medicare beneficiaries and totaling roughly $15K in drug spend, split 96% brand-name and 4% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Oncology Pharmacist is a narrow specialty nationwide, with 1,699 enrolled providers across 50 states and an average of 160 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

500 W FORT ST
BOISE, ID 83702

Provider Details

NPI 1952791071
Specialty Oncology Pharmacist
Credentials PHARM.D., BCOP
Gender Female
NPI Issued 01/27/2015

Brand vs generic prescribing mix · Brand-heavy

STEPHANIE MAGDANZ, PHARM.D., BCOP — brand share 96.0%
Specialty average (est.)

96% brand-name claims vs 4% generic, on 72 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

72
Total Claims
$15K
Total Drug Cost
64
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
74
Total Day Supply
218
Brand vs Generic
96% brand / 4% generic
Brand Drug Cost
$15K

Patient Demographics

Average Patient Age
74.2 years
Avg HCC Risk Score
0.78
Gender Split
61% female / 39% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Shingrix
Varicella-Zoster Ge/As01b/Pf
37
Arexvy
Rsvpref3 Antigen/As01e/Pf
14

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Oncology Pharmacist Overview

How STEPHANIE MAGDANZ, PHARM.D., BCOP fits within the Oncology Pharmacist landscape nationally.

1,699
Oncology Pharmacist Providers in US
50
States with Oncology Pharmacist
160
Avg Claims per Provider

STEPHANIE MAGDANZ, PHARM.D., BCOP's 72 claims are below the specialty average of 160.

Nearby Oncology Pharmacist Providers in Idaho

Other clinicians with the same primary specialty enrolled in Idaho, drawn from the same CMS NPPES roster as MAGDANZ.

Compare Oncology Pharmacist nationally: see state-by-state distribution →

Frequently Asked Questions

What is STEPHANIE MAGDANZ, PHARM.D., BCOP's specialty?
STEPHANIE MAGDANZ, PHARM.D., BCOP specializes in Oncology Pharmacist and practices in BOISE, Idaho. Credentials: PHARM.D., BCOP.
How much does STEPHANIE MAGDANZ, PHARM.D., BCOP prescribe under Medicare Part D?
In 2023, STEPHANIE MAGDANZ, PHARM.D., BCOP wrote 72 Medicare Part D claims totaling $15K in drug costs for 64 beneficiaries.
Where is STEPHANIE MAGDANZ, PHARM.D., BCOP located?
STEPHANIE MAGDANZ, PHARM.D., BCOP is located at 500 W FORT ST, BOISE, ID, 83702. Phone: (208) 422-1000.
What is STEPHANIE MAGDANZ, PHARM.D., BCOP's NPI number?
STEPHANIE MAGDANZ, PHARM.D., BCOP's National Provider Identifier (NPI) is 1952791071, issued on 01/27/2015.
Does STEPHANIE MAGDANZ, PHARM.D., BCOP prescribe more brand-name or generic drugs?
STEPHANIE MAGDANZ, PHARM.D., BCOP's prescribing is 96% brand-name and 4% generic drugs by claim count, with $15K in brand drug costs.
How many Oncology Pharmacist providers are there in the US?
There are 1,699 Oncology Pharmacist providers across 50 states in the US. The average Oncology Pharmacist provider writes 160 Medicare Part D claims per year.
What drugs does STEPHANIE MAGDANZ, PHARM.D., BCOP prescribe most often?
Based on 2023 Medicare Part D data, STEPHANIE MAGDANZ, PHARM.D., BCOP's most frequently prescribed drugs include Shingrix, Arexvy. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does STEPHANIE MAGDANZ, PHARM.D., BCOP accept Medicare?
STEPHANIE MAGDANZ, PHARM.D., BCOP appears in CMS Medicare data with 72 Part D claims and 64 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify STEPHANIE MAGDANZ, PHARM.D., BCOP's credentials?
STEPHANIE MAGDANZ, PHARM.D., BCOP's NPI is 1952791071 with credentials PHARM.D., BCOP. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology